Mi_2022_Bioorg.Med.Chem.Lett_60_128574

Reference

Title : Development of naringenin-O-carbamate derivatives as multi-target-directed liagnds for the treatment of Alzheimer's disease - Mi_2022_Bioorg.Med.Chem.Lett_60_128574
Author(s) : Mi J , He Y , Yang J , Zhou Y , Zhu G , Wu A , Liu W , Sang Z
Ref : Bioorganic & Medicinal Chemistry Lett , 60 :128574 , 2022
Abstract :

In this work, a series of naringenin-O-carbamate derivatives was designed and synthesized as multifunctional agents for the treatment of Alzheimer's disease (AD) through multi-target-directed ligands (MTDLs) strategy. The biological activity in vitro showed that compound 3c showed good antioxidant potency (ORAC = 1.0 eq), and it was a reversible huAChE (IC(50) = 9.7 microM) inhibitor. In addition, compound 3c significantly inhibited self-induced Abeta(1-42) aggregation, and it could activate UPS degradation pathway in HT22 cells and clear the aggregated proteins associated with AD. Moreover, compound 3c was a selective metal chelator, and it significantly inhibited and disaggregated Cu(2+)-mediated Abeta(1-42) aggregation. Furthermore, compound 3c displayed remarkable neuroprotective effect and anti-inflammatory property. Interestingly, compound 3c displayed good hepatoprotective effect by its antioxidant activity. More importantly, compound 3c demonstrated favourable blood-brain barrier penetration in vitro and drug-like property. Therefore, compound 3c was a promising multifunctional agent for the treatment of AD.

PubMedSearch : Mi_2022_Bioorg.Med.Chem.Lett_60_128574
PubMedID: 35065231

Related information

Inhibitor DECF

Citations formats

Mi J, He Y, Yang J, Zhou Y, Zhu G, Wu A, Liu W, Sang Z (2022)
Development of naringenin-O-carbamate derivatives as multi-target-directed liagnds for the treatment of Alzheimer's disease
Bioorganic & Medicinal Chemistry Lett 60 :128574

Mi J, He Y, Yang J, Zhou Y, Zhu G, Wu A, Liu W, Sang Z (2022)
Bioorganic & Medicinal Chemistry Lett 60 :128574